Biofrontera (NASDAQ:BFRI – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Biofrontera to related businesses based on the strength of its risk, dividends, valuation, profitability, earnings, analyst recommendations and institutional ownership.
Institutional & Insider Ownership
10.1% of Biofrontera shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 8.1% of Biofrontera shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings and target prices for Biofrontera and its competitors, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biofrontera | 1 | 1 | 1 | 0 | 2.00 |
| Biofrontera Competitors | 7820 | 13783 | 25794 | 1036 | 2.41 |
As a group, “Pharmaceuticals” companies have a potential upside of 25.04%. Given Biofrontera’s competitors stronger consensus rating and higher possible upside, analysts clearly believe Biofrontera has less favorable growth aspects than its competitors.
Profitability
This table compares Biofrontera and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biofrontera | -13.78% | -145.81% | -31.30% |
| Biofrontera Competitors | -2,393.19% | -220.45% | -16.12% |
Valuation and Earnings
This table compares Biofrontera and its competitors revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Biofrontera | $41.71 million | -$10.54 million | -1.92 |
| Biofrontera Competitors | $3.54 billion | $3.17 billion | 553.79 |
Biofrontera’s competitors have higher revenue and earnings than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
Biofrontera has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Comparatively, Biofrontera’s competitors have a beta of -0.05, suggesting that their average share price is 105% less volatile than the S&P 500.
Summary
Biofrontera competitors beat Biofrontera on 10 of the 13 factors compared.
Biofrontera Company Profile
Biofrontera Inc. (NASDAQ:BFRI) is a specialty pharmaceutical company focused on developing and commercializing prescription dermatology products, with an emphasis on treatments for precancerous and cancerous skin conditions. The company primarily serves the U.S. dermatology market through a commercial organization that supports physicians and other healthcare providers. Biofrontera’s principal product is Ameluz (aminolevulinic acid hydrochloride) topical gel, a prescription medication used with photodynamic therapy to treat actinic keratoses.
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.
